Salarius Pharmaceuticals and Decoy Therapeutics Merge to Enhance Cancer Treatment Pipeline

Introduction

SALARIUS PHARMACEUTICALS INC (NASDAQ: SLRX) is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on correcting dysregulated gene expression in cancer cells. Its lead programs include seclidemstat (SP-2577), a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and other solid tumors, and SP-3164, an oral targeted protein degrader in IND-enabling studies. On July 29, 2025, SLRX shares closed at $1.86, representing a 150.98% increase, with a trading volume of 6,136,656 shares on the NASDAQ exchange.

Corporate Structure

Founded in 2011, Salarius employs between 11 and 50 people, with headquarters located in the Texas Medical Center Innovation facility. Key executives include David Arthur (Chief Executive Officer), Tess Burleson, CPA, MBA (Chief Operating Officer), and William McVicar, PhD (Chair of the Board). Salarius has received a three-year $16.1 million award from the Cancer Prevention and Research Institute of Texas and financial support from the National Pediatric Cancer Foundation. Collaborative partners include the MD Anderson Cancer Center.

Biopharmaceuticals by little plant

Recent Developments and News

On January 13, 2025, Salarius and Decoy Therapeutics announced a definitive merger agreement to create a combined entity named Decoy Therapeutics. The transaction is expected to integrate Decoy’s IMP3ACT™ AI/ML-driven peptide conjugate platform alongside Salarius’s SP-3164 program, which targets transcription factors IKZF1 and IKZF3. Salarius continues to advance seclidemstat through:

• A company-sponsored Phase 1/2 trial in relapsed/refractory Ewing sarcoma, including combination studies with topotecan and cyclophosphamide
• An investigator-initiated Phase 1/2 trial at MD Anderson for myelodysplastic syndromes and chronic myelomonocytic leukemia, in combination with azacitidine

Recent SEC filings include Form 8-K submissions on July 14, July 21, and July 28, 2025, reporting material agreements and corporate developments.

Financial and Strategic Analysis

Salarius is currently pre-revenue, funding operations through grants, partnerships, and equity markets. The 150.98% increase in stock price on July 29, 2025, aligns with heightened investor interest in the merger with Decoy Therapeutics and ongoing pipeline development. Strategically, Salarius integrates targeted protein inhibition (TPIs) and targeted protein degradation (TPDs) to address both liquid and solid tumors. The merger introduces a peptide conjugate discovery platform, potentially expanding Salarius’s focus into respiratory infectious diseases and gastrointestinal oncology. Key upcoming catalysts include the shareholder vote to finalize the merger, IND submission, trial initiation for SP-3164, and clinical data readouts from seclidemstat combination studies.

Market Position and Industry Context

Salarius operates within the oncology sector, focusing on epigenetic regulators and protein degradation pathways. Seclidemstat holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations for Ewing sarcoma, which accounts for approximately 500 new cases annually in the United States. The SP-3164 program is entering the molecular glue and PROTAC domains, areas that have garnered significant investment in the biopharmaceutical sector. Collaboration with MD Anderson contributes to scientific validation, while the emphasis on rare cancers and hematologic conditions may support accelerated regulatory pathways and the potential for broader indications, such as acute myeloid leukemia, which had nearly 20,000 new cases in the U.S. in 2020.

TL;DR

On January 13, 2025, Salarius Pharmaceuticals agreed to merge with Decoy Therapeutics, integrating its SP-3164 program with Decoy’s AI/ML peptide conjugate platform. As of July 29, 2025, SLRX shares closed at $1.86 (up 150.98%). Seclidemstat is in Phase 1/2 trials for Ewing sarcoma and hematologic cancers, while SP-3164 remains in IND-enabling studies, with clinical trials anticipated later in 2025. Upcoming milestones include the completion of the merger and initiation of clinical studies for SP-3164.